46,XX ovotesticular difference of sex development is a rare genetic/congenital condition that affects how the reproductive organs form before birth. People with this condition may have both ovarian and testicular tissue, and the external genitals can look more typically male, female, or in between. Many people first hear about 46,XX ovotesticular difference of sex development when questions arise in newborn exams or during puberty. Care often includes careful hormonal checks, imaging, and sometimes surgery, with ongoing endocrine and urologic or gynecologic care. Most individuals live a normal lifespan, and treatment focuses on safety, fertility counseling, and supportive hormone management tailored over time.
Overview
46,xx ovotesticular difference of sex developmentSymptoms
46,XX ovotesticular difference of sex development often first shows at birth with atypical genital appearance. Later, features can include undescended gonads, hernias, or mixed puberty changes (breast development with facial hair), and possible cyclic genital bleeding or fertility challenges.
Outlook and prognosis
Most people with 46,XX ovotesticular difference of sex development do well with tailored support and regular follow-up. Fertility varies; some can produce eggs or sperm, and options like assisted reproduction may help. Care typically focuses on hormone balance, genital health, and personal goals.
Causes and risk factors
Causes of 46,XX ovotesticular difference of sex development are usually genetic—often SRY gene translocation, or changes that increase SOX9 or reduce WNT/RSPO1 signaling. Most cases are new (not inherited); rare families show autosomal or X‑linked patterns. No proven environmental risks.
Genetic influences
Genetics play a central role in 46,XX ovotesticular difference of sex development. Variations can involve SRY translocation or changes in ovary‑testis pathway genes (e.g., SOX9 enhancers, NR5A1), but the exact cause is sometimes unknown. Genetic counseling and testing are often recommended.
Diagnosis
Doctors assess clinical features at birth or later and order hormone levels, ultrasound or MRI, and chromosomal and gene tests. The genetic diagnosis of 46,XX ovotesticular difference of sex development is confirmed by these findings alongside specialist review.
Treatment and drugs
Treatment for 46,XX ovotesticular difference of sex development is personalized and guided by your goals, age, hormone levels, and overall health. Care often includes hormone support, careful gender-affirming counseling, and, when helpful, staged surgeries. Ongoing follow-up monitors puberty, fertility options, bone health, and wellbeing.
Symptoms
People with 46,XX ovotesticular difference of sex development may notice traits related to genital appearance, puberty, and fertility, which can vary widely. Features vary from person to person and can change over time. Early features of 46,XX ovotesticular difference of sex development are often seen at birth, though some become clear around puberty.
The genitals may not look clearly male or female at birth. This can include a larger clitoris or small penis-like structure, partial labial fusion, or a single opening. Teams may recommend imaging to better understand the anatomy.
One or both gonads may not be felt in the scrotum or groin. A clinician may find them higher in the groin or abdomen on ultrasound. Regular checkups help track their position and health.
People with 46,XX ovotesticular difference of sex development may have tissue with ovarian and testicular function on one or both sides. This is usually found on imaging or during surgery, not something you can see or feel. It can influence hormone levels, puberty, and fertility.
A uterus or fallopian tubes may be present on one side, both sides, or absent in 46,XX ovotesticular difference of sex development. These features are typically seen on ultrasound or MRI. They can affect periods, pregnancy potential, and the type of care needed.
How people usually first notice 46,xx ovotesticular difference of sex development?
Many families first notice something unusual at birth, such as genitalia that don’t look typically male or female, which prompts the care team to examine hormone levels and internal reproductive structures. Sometimes the first signs of 46,XX ovotesticular difference of sex development are found on a prenatal or newborn ultrasound that shows both ovarian and testicular tissue, or later in early childhood when a doctor notices differences during a routine exam. In a few cases, how 46,XX ovotesticular DSD is first noticed is during puberty, when expected changes don’t happen or occur in a mixed pattern, leading to further testing.
Types of 46,xx ovotesticular difference of sex development
46,XX ovotesticular difference of sex development (DSD) can look different from one person to the next because the mix of ovarian and testicular tissue can vary in amount and where it’s located. Some have more testicular-type function, others more ovarian-type function, and many have a mixed pattern that shifts across childhood, puberty, and adulthood. Clinicians often describe them in these categories: patterns dominated by ovarian function, dominated by testicular function, or mixed/alternating function over time. Not everyone will experience every type, and the balance can change, so discussions about types of 46,XX ovotesticular DSD focus on what hormones and tissues are most active at a given time.
Ovary-predominant pattern
Ovarian tissue is more active, which may support menstrual cycles and estrogen-driven puberty. Genital appearance may be mostly female-typical at birth, sometimes with subtle differences. Fertility potential may be present on the ovarian side depending on anatomy.
Testis-predominant pattern
Testicular tissue is more active, often leading to higher testosterone and more male-typical genital appearance at birth. Puberty changes may follow a more testosterone-led course. Fertility potential is usually limited but depends on how much functional testicular tissue is present.
Mixed/alternating function
Both ovarian and testicular tissues are present and can be variably active across time. Some people notice changes at puberty or later, like shifts in hair growth, voice, or menstrual bleeding patterns. The balance of symptoms can shift over time.
SRY-positive variant
The SRY gene is found on one chromosome despite the 46,XX pattern, which can drive more testicular development. This may track with testis-predominant or mixed features. Hormone levels and genital appearance vary with how active those tissues are.
SRY-negative variant
No SRY gene is detected, and testicular tissue may still develop through other gene pathways. Features range from ovary-predominant to mixed. Care teams often rely on hormone testing and imaging over time to guide plans.
What genetics can tell you about symptoms
Some people with 46,XX ovotesticular DSD have variants in genes like SRY (rarely present on an X or autosome), SOX9 regulators, or RSPO1 that shift fetal gonad development toward mixed ovarian–testicular tissue. This can lead to ambiguous genitalia at birth, atypical puberty patterns, and variable fertility.
Causes and risk factors
Most causes and risk factors of 46,XX ovotesticular difference of sex development are genetic and present from birth. Family history is uncommon, because many cases arise as new changes. This can include the SRY gene being moved onto another chromosome or extra activity near SOX9. There are no proven lifestyle or environmental causes. Having a gene change doesn’t mean you’ll definitely develop the condition.
Environmental and biological risk factors
46,XX ovotesticular difference of sex development is rare and begins very early in fetal growth. Most risk factors discussed for this condition are biological, tied to how the early sex glands form and how hormones signal in the womb. Researchers are still exploring how outside influences interact with our inner biology. Below are environmental and biological risk factors for 46,XX ovotesticular difference of sex development, and where evidence is currently limited.
Very early in pregnancy, signals that guide the sex glands to become ovaries or testes can vary in timing or strength. This internal difference can lead to both ovarian and testicular tissue forming in 46,XX ovotesticular DSD. These events happen in the first trimester.
The mix of sex hormones around the fetus shapes the internal reproductive structures and the outer genitals. When hormone levels do not match the type of tissue present, features of both sexes may develop in 46,XX ovotesticular DSD. This is a biological, body-based factor.
The placenta helps regulate the fetus’s hormone environment. Unusual placental hormone processing can shift that balance, but clear links to this diagnosis are limited. This is considered a biological influence rather than an outside exposure.
Conditions that raise or lower a pregnant person’s sex hormones can affect the fetal hormone setting. These changes can alter genital appearance but are not known to cause ovary-and-testis tissue together. Care teams sometimes check this history to understand the prenatal environment.
Genetic risk factors
The genetic causes of 46,xx ovotesticular difference of sex development involve changes in a small set of genes that push developing sex glands toward testis tissue despite XX chromosomes. Some risk factors are inherited through our genes. These changes can include a moved or extra copy of a sex-determining gene, or a tweak in the nearby on/off switches that control when a gene is active. Genetic testing can sometimes spot the exact change and help clarify recurrence risk in a family.
SRY translocation: The SRY gene, usually carried on the Y chromosome, can be accidentally moved onto an X chromosome or another chromosome. In some people with 46,xx ovotesticular difference of sex development, this misplaced SRY turns on testis development. It most often arises as a new change rather than being inherited.
SOX9 upregulation: Extra copies of control DNA near SOX9 can boost this gene’s activity at the wrong time. Higher SOX9 activity can trigger testis tissue in 46,xx ovotesticular difference of sex development. These copy-number changes may be passed down or occur for the first time.
SOX3 duplication: Duplications involving SOX3 on the X chromosome can switch on pathways that mimic SRY. This can lead to mixed ovarian and testicular tissue in someone with 46,XX chromosomes. Families may have more than one affected member if the duplication is inherited.
RSPO1 variants: Changes in both copies of the RSPO1 gene can disrupt typical ovarian development. This autosomal recessive pattern can allow testis tissue to form in 46,XX individuals. Some families also notice skin findings, such as thickened skin on the palms and soles.
NR5A1 variants: Specific changes in the NR5A1 (also called SF1) gene have been linked to 46,xx ovotesticular difference of sex development. These rare variants can tilt early gonad development toward testis pathways even with XX chromosomes. They may be inherited or occur de novo.
Unknown genetics: In a number of cases, no single gene change is found with current tests. This does not rule out a genetic cause—some changes are very small or lie in regions we do not yet scan well. As testing improves, more causes are being discovered.
Family history: When a known gene change is present in a parent, the chance of 46,xx ovotesticular difference of sex development can be higher for future children. The pattern depends on the gene involved, such as autosomal recessive inheritance for RSPO1. Genetic counseling can outline specific chances and testing options.
Lifestyle risk factors
46,xx ovotesticular difference of sex development is not caused by lifestyle, but daily habits can shape symptoms, hormone balance, and long-term health. Tailored choices may support bone strength, metabolic health, sexual function, and recovery after procedures or during hormone therapy. Understanding how lifestyle affects 46,xx ovotesticular difference of sex development can help you work with your care team to prevent complications and feel your best.
Regular weight‑bearing and resistance exercise helps preserve bone density when sex-steroid levels are low or variable. It can also improve insulin sensitivity and mood during hormone adjustments.
Adequate calcium, vitamin D, and protein support bone strength and surgical healing when relevant. Balanced nutrition helps maintain stable energy and weight, which can influence estrogen and testosterone balance.
Higher body fat increases aromatase activity, which can shift estrogen–androgen balance and complicate symptom control. Obesity also raises clot risk when using estrogen, while being underweight can worsen bone loss.
Short or irregular sleep can disturb the hypothalamic–pituitary–gonadal axis, nudging sex-steroid levels and symptoms off balance. Good sleep supports mood, recovery, and hormone therapy responses.
Risk prevention
46,XX ovotesticular difference of sex development is present from birth, so prevention focuses on avoiding complications and supporting long‑term health. Different people need different prevention strategies—there’s no single formula. The most effective steps center on early, team-based care, regular monitoring, and thoughtful planning before any irreversible choices. Families and clinicians can work together to protect fertility, hormones, growth, and well-being over time.
Noticing early symptoms of 46,XX ovotesticular difference of sex development, like atypical genital appearance or unexpected puberty changes, can lead to timely specialist care. Early assessment helps prevent delays in hormone support and reduces avoidable surgeries.
Some ovotesticular tissues can carry a small risk of tumors. Regular exams and imaging or lab checks, guided by your care team, can catch changes early.
Routine hormone testing helps spot low or fluctuating levels that can affect growth, mood, energy, and sexual development. Adjusting treatment early can protect bone, heart, and metabolic health.
When surgery is considered, careful timing and a conservative approach can lower risks and avoid procedures that may not be necessary. Second opinions and shared decision-making help tailor choices to the individual.
Transmission
46,xx ovotesticular difference of sex development is not contagious; it cannot be caught or spread between people. It starts before birth due to genetic changes that affect how the gonads form, and in many families it happens for the first time with no prior history. Less commonly, genetic transmission of 46,xx ovotesticular difference of sex development can occur, and the inheritance pattern depends on which gene is involved, so the chance of it happening again in a family can vary. Genetic testing and counseling can help clarify how 46,xx ovotesticular difference of sex development is inherited in your specific situation and estimate the recurrence risk for future pregnancies.
When to test your genes
Consider genetic testing if a baby’s genitals look atypical at birth, puberty brings unexpected changes (like absent or asymmetric development), or ultrasound/labs suggest mixed ovarian–testicular tissue. Testing also helps tailor hormone care and fertility planning. If a close relative has a DSD, discuss earlier evaluation with a specialist.
Diagnosis
Questions often arise right after birth, when genital appearance or early hormone patterns don’t match expectations, and families want clear answers to guide care. Doctors usually begin with a careful exam and a few targeted tests, then build a fuller picture over time. Early and accurate diagnosis can help you plan ahead with confidence. In many cases, clinical clues are confirmed by lab work and imaging, and the genetic diagnosis of 46,XX ovotesticular difference of sex development is established with chromosome and gene testing.
Doctors look for features such as genital appearance, the position of the urethra, and whether both gonads can be felt. These clinical features help decide which tests come next. Findings guide timing and urgency of further evaluation.
Blood tests check baseline hormones and how they change over time. Patterns can suggest the presence of both ovarian and testicular tissue. Repeat tests may be needed to see how hormones respond during mini‑puberty in infancy.
A karyotype confirms whether chromosomes are 46,XX in this condition. It can also check if any Y‑chromosome material is present. This step anchors the diagnosis of 46,XX ovotesticular difference of sex development.
Targeted testing looks for small pieces of Y‑related genes (such as SRY) that may have moved, or changes near genes that control gonadal development. Gene panels or chromosomal microarray can help detect these changes. Results can clarify cause and guide counseling.
Stages of 46,xx ovotesticular difference of sex development
46,xx ovotesticular difference of sex development does not have defined progression stages. It’s present from birth and experiences may shift with life milestones like infancy, puberty, and adulthood, but it doesn’t follow a step-by-step decline or predictable sequence. Early symptoms of 46,xx ovotesticular difference of sex development may include genital differences noticed at birth or unexpected changes during puberty. Different tests may be suggested to help confirm the diagnosis, including a physical exam, hormone blood tests, imaging (ultrasound or MRI), and chromosome testing, with follow-up over time to monitor growth, puberty, and fertility.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with 46,XX ovotesticular difference of sex development, health and life expectancy are close to typical, especially with attentive, coordinated care. Daily life tends to center on monitoring hormone levels, supporting puberty and adult hormone balance, and addressing fertility questions early. Some may choose surgeries to align anatomy with function or comfort, while others focus on watchful follow-up and hormone therapy; both paths can be safe when planned with experienced teams.
Doctors call this the prognosis—a medical word for likely outcomes. Early care can make a real difference, particularly for newborns and children, because careful planning can reduce later surgeries and help protect future fertility. In teens and adults, the most common issues are hormone changes, uneven or delayed puberty, and, less often, cyclic pelvic pain if ovarian tissue is active. Rarely, certain gonadal tissues can develop tumors over time; regular imaging and lab checks help manage this risk, which is generally lower than in some other sex chromosome conditions.
Everyone’s journey looks a little different. Most people with 46,XX ovotesticular difference of sex development have typical overall survival; deaths directly due to this condition are uncommon in current reports. What matters most is ongoing follow-up with endocrinology, urology/gynecology, and primary care to fine-tune hormones, screen for tumor risk when appropriate, and discuss fertility preservation options. If you’re wondering about early symptoms of 46,XX ovotesticular difference of sex development that may affect the future—such as ambiguous genitalia at birth or unexpected puberty patterns—talk with your care team about what to watch for and when to check in.
Long-term effects
Looking ahead, the long-term picture centers on growth, puberty, hormone balance, and future fertility. For people with 46,XX ovotesticular difference of sex development, outcomes range from typical development to needs that change over time. Long-term effects vary widely, and what matters most is how the gonadal tissue functions through childhood and adulthood.
At birth or in early childhood, genital appearance can vary and may not fit typical male or female patterns. Internal reproductive structures may include both ovarian and testicular tissue in different proportions.
Pubertal changes can be mixed, with some developing breast tissue and menstrual bleeding while others show voice deepening or increased body hair. The timing and pace of changes often reflect how active each type of gonadal tissue is.
Hormone levels can shift across childhood, puberty, and adulthood. These shifts can influence energy, body composition, and how secondary sex characteristics appear over time.
Some have regular or occasional menstrual bleeding, while others never menstruate. Bleeding patterns may change across adolescence and adulthood if hormone production changes.
How is it to live with 46,xx ovotesticular difference of sex development?
Living with 46,XX ovotesticular difference of sex development can mean navigating medical follow-up, questions about puberty, fertility, and hormone balance, alongside decisions about identity and disclosure at school, work, or within family. Daily life often looks typical, but there may be periodic appointments for hormone checks, imaging, or fertility counseling, and sometimes surgery is considered for specific health reasons rather than appearance alone. Many find it helpful to build a supportive circle—partners, family, trusted clinicians, and peer communities—so conversations about bodies and identity feel safe and respectful. For those around the person, listening, using affirmed names and pronouns, and avoiding assumptions about gender or fertility are simple ways to reduce stress and strengthen trust.
Treatment and drugs
Treatment for 46,XX ovotesticular difference of sex development focuses on health, safety, and future well-being rather than rushing into permanent decisions. Care is usually guided by a specialized team—endocrinology, urology, gynecology, genetics, psychology—who track hormone levels, genital anatomy, fertility potential, and overall growth, and then tailor care over time; treatment plans often combine several approaches. Early steps may include hormone therapy to support puberty or address hormone imbalance, and surgery may be considered to improve function (such as allowing comfortable urination, reducing cancer risk in certain gonadal tissues, or aligning internal anatomy), with timing chosen carefully and with family input when children are involved. Medicines that ease symptoms are called supportive therapies, and can include short-term hormones, vitamin D and calcium if needed for bone health, and treatments for menstrual or metabolic issues. Although living with 46,XX ovotesticular difference of sex development can feel overwhelming, ongoing counseling, fertility guidance, and regular follow-up help many people make informed choices and live well.
Non-drug treatment
Care for 46,XX ovotesticular difference of sex development centers on supporting healthy growth, comfort, and family decision-making over time. Non-drug treatments often lay the foundation for day-to-day wellbeing, with medical and emotional support tailored to each person. Plans are individualized and can change as needs evolve. Regular check-ins help families pace decisions and avoid rushing into steps they’re not ready for.
A coordinated team (endocrinology, urology/gynecology, psychology, genetics) works together so care feels seamless. They help align medical findings with family goals and values.
Supportive therapies can make it easier to process emotions, navigate decisions, and reduce stress. Counselors also coach communication skills for talking with schools, relatives, or partners.
Specialists explain what is known about the genetics, what remains uncertain, and what it may mean for relatives. They review testing options and discuss future family planning in plain language.
Care focuses on how a child or teen experiences their body and identity over time. Not every approach works the same way, so support is flexible and paced to the person’s comfort.
Your genes may have an impact on how drugs work for you
Medicines used in 46,XX ovotesticular difference of sex development can act differently depending on genes that affect hormone production, receptors, and how the liver processes drugs. This means dosing and choice of therapies may be tailored to your genetic profile.
Pharmacological treatments
Medicines for 46,XX ovotesticular difference of sex development focus on managing puberty, hormone balance, and day-to-day comfort. Doctors adjust treatment plans regularly based on growth, lab results, and personal goals. Care is individualized, and hormone therapy options for 46,XX ovotesticular difference of sex development can evolve over time with close monitoring.
Testosterone enanthate or cypionate injections, or transdermal gels/patches, can start or maintain masculinizing puberty. Dosing may be increased or lowered gradually to build changes safely and monitor for side effects such as acne, red blood cell changes, and mood shifts. Regular labs check hematocrit, liver enzymes, and lipids.
Oral or transdermal 17‑beta estradiol, or estradiol valerate injections, can start or maintain feminizing puberty. Not everyone responds to the same medication in the same way. A progestin may be added later if a uterus is present to protect the uterine lining.
Medroxyprogesterone or norethindrone can lighten or stop periods and ease cramping. A levonorgestrel intrauterine device is another option for menstrual control in people with 46,XX ovotesticular difference of sex development. These medicines can also protect the uterine lining if you’re taking estrogen.
Leuprolide, triptorelin, or a histrelin implant can temporarily pause puberty while decisions are made and plans are set. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). Effects are reversible once the medicine is stopped.
Genetic influences
In 46,XX ovotesticular difference of sex development, the chromosomes are typically XX, but some of the early signals that shape the gonads tilt toward testis development. Extra copies or overactive control switches near a gene called SOX9 can push testis tissue to form even without a Y chromosome. Less often, the SRY gene—normally on the Y chromosome—may be moved onto another chromosome, or rare changes in RSPO1 or WNT4 can shift the balance between ovarian and testicular development. Many people have no single identifiable variant on routine blood testing; sometimes low-level mosaic changes or gene differences are present only in the gonads, so standard tests may miss them. Most cases are not inherited, and family history is uncommon; when the genetic causes of 46,XX ovotesticular difference of sex development are identified, the inheritance pattern depends on the specific gene, and relatives may be offered testing. Understanding whether a condition is inherited can guide next steps.
Is 46,xx ovotesticular difference of sex development genetic?
Genetics play a central role in 46,XX ovotesticular difference of sex development. Variations can involve SRY translocation or changes in ovary‑testis pathway genes (e.g., SOX9 enhancers, NR5A1), but the exact cause is sometimes unknown. Genetic counseling and testing are often recommended.
Pharmacogenetics—how genetics influence drug effects
In 46,XX ovotesticular difference of sex development, treatment plans often include carefully tailored hormone therapy—sometimes estrogen, sometimes testosterone, and at times medicines that pause puberty—so medication choices and doses are individualized. Genes can influence how quickly you clear estrogen or testosterone, which can change how strong an effect a given dose has and how often it needs to be adjusted. Inherited differences in the enzymes that break down these hormones can make someone process them more slowly or more quickly, so doctors usually monitor symptoms, growth, and blood levels and adjust step by step. Safety matters too: if estrogen is used, certain inherited clotting traits (such as Factor V Leiden) can raise the risk of blood clots, which may lead the team to choose a lower‑risk route like a skin patch rather than tablets. By contrast, testosterone dosing is guided mostly by symptom relief and blood tests, because routine pharmacogenetic testing hasn’t yet been shown to improve outcomes for sex‑steroid therapy. Some families ask about pharmacogenetic testing for hormone therapy in 46,XX ovotesticular difference of sex development; it can be discussed if side effects or unexpected lab results occur, but choices will still lean on personal goals, stage of development, other medicines, and close follow‑up.
Interactions with other conditions
Living with 46,xx ovotesticular difference of sex development can intersect with other health issues in ways that affect everyday life. Hormone therapy used in some care plans may interact with other diseases: for example, estrogen can raise clotting risk in people with a history of blood clots or migraines with aura, while testosterone can worsen untreated sleep apnea or shift cholesterol levels, so teams often tailor doses and monitoring. Urinary tract differences or past genital surgeries can make urinary infections more likely, and conditions like diabetes can make those infections harder to clear. Doctors call it a “comorbidity” when two conditions occur together, and mental health conditions such as anxiety or depression may influence how someone copes with decisions about surgery, hormones, or fertility planning. There is a small but real risk of tumors in ovotesticular tissue, so if someone also has a family tendency to certain cancers, follow-up plans may be more frequent. Early symptoms of 46,xx ovotesticular difference of sex development can overlap with other conditions that affect genital development, which is why coordinated, multidisciplinary care helps avoid missed problems and unnecessary treatments.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described infants whose physical traits at birth didn’t fit typical male or female patterns, and family stories sometimes noted unusual pubertal changes in teens. Midwives, doctors, and communities often used local terms, and many medical notes focused on what could be seen rather than why it happened. Some adults recalled late decisions about identity or surgery made in childhood, reflecting older practices and limited understanding at the time.
First described in the medical literature as “true hermaphroditism,” the condition now called 46,XX ovotesticular difference of sex development was initially grouped with several other variations. Early reports emphasized visible features and anatomy after surgery or, in rare cases, autopsy. Over time, descriptions became more precise, noting that some people with ovotesticular DSD had both ovarian and testicular tissue, and that hormone levels and chromosome patterns did not always match outward traits. As medical science evolved, specialists recognized that language matters and moved away from stigmatizing terms toward respectful, person-first wording.
In recent decades, knowledge has built on a long tradition of observation. Clinicians learned that ovotesticular DSD is not one single story but many. For some, early symptoms of ovotesticular DSD are noticed in the newborn period; for others, questions arise around puberty, such as unexpected breast development, voice changes, or fertility concerns. Shifts in care also occurred: instead of hurried decisions, more centers now use a team approach, give families time to understand options, and support the individual’s developing sense of self.
Genetics added important clarity. While people with 46,XX ovotesticular DSD typically have two X chromosomes, studies found that certain genes involved in testis development can act like a dimmer switch turned up or down, leading to mixed gonadal tissue. Researchers also recognized that the same outward features can arise from different genetic pathways, and the same pathway can lead to different features in different people. This helped explain why experiences vary and why personalized care is essential.
Across cultures and centuries, 46,XX ovotesticular difference of sex development has been observed in different ways. Not every early description was complete, yet together they built the foundation of today’s knowledge. Looking back helps explain current care: more careful diagnosis, respectful language, and shared decision-making. The historical arc—from scattered case notes to coordinated, evidence-based support—continues to guide how clinicians and families navigate health, identity, and wellbeing for people living with ovotesticular DSD.